此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

A Phase 2 Study of RCI001 Ophthalmic Solution in Participants With Dry Eye Disease

2026年6月1日 更新者：Rudacure

A Phase 2, Multi-center, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye

This is a Phase 2 clinical study designed to evaluate the safety and efficacy of 0.25% RCI001 Ophthalmic Solution compared with placebo in participants with dry eye disease.

The study will enroll adults with dry eye disease. After a 2-week run-in period with placebo ophthalmic solution, eligible participants will be randomly assigned to receive either 0.25% RCI001 Ophthalmic Solution or placebo ophthalmic solution in both eyes for 4 weeks. Study treatment will be administered either twice daily or four times daily, depending on the assigned dosing regimen.

The main purpose of the study is to determine whether RCI001 improves the signs and symptoms of dry eye disease compared with placebo. The primary assessments include total corneal fluorescein staining and ocular discomfort at Day 28. Safety will be assessed through eye examinations, visual acuity, intraocular pressure, drop comfort, and adverse event monitoring.

研究概览

地位

尚未招聘

条件

干预/治疗

详细说明

This is a multi-center, randomized, double-masked, placebo-controlled Phase 2 study evaluating 0.25% RCI001 Ophthalmic Solution in participants with dry eye disease.

The study will include approximately 6 weeks of participation for each participant, consisting of a 2-week run-in period followed by a 4-week treatment period. Approximately 400 participants are expected to be screened, and approximately 200 eligible participants will be randomized, with approximately 50 participants assigned to each treatment group.

During the run-in period, participants who qualify at screening will receive placebo ophthalmic solution in both eyes according to either a twice-daily or four-times-daily dosing regimen. At the end of the run-in period, eligible participants will be randomized to continue the same dosing frequency and receive either 0.25% RCI001 Ophthalmic Solution or placebo ophthalmic solution bilaterally for 4 weeks.

The four treatment groups are:

0.25% RCI001 Ophthalmic Solution twice daily; placebo ophthalmic solution twice daily; 0.25% RCI001 Ophthalmic Solution four times daily; and placebo ophthalmic solution four times daily.

The study will include four scheduled visits: screening at Day -14, baseline/randomization at Day 1, follow-up at Day 14, and end-of-treatment/study exit at Day 28. Controlled Adverse Environment (CAE) assessments will be used as part of the study procedures.

The primary efficacy endpoints are total corneal fluorescein staining and ocular discomfort assessed before CAE exposure at Day 28. Secondary efficacy assessments include additional ocular staining measures, conjunctival redness, Schirmer's test, tear film break-up time, Ocular Surface Disease Index, ocular discomfort scores, visual analog scale symptoms, and daily symptom diary data.

Safety assessments include visual acuity, slit-lamp biomicroscopy, drop comfort, adverse event monitoring, intraocular pressure, and dilated fundoscopy. The study is designed to compare RCI001 with the corresponding placebo dosing regimen and to evaluate the optimal dosing frequency of RCI001 in the treatment of the signs and symptoms of dry eye disease.

研究类型

介入性

注册 (估计的)

200

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  1. At least 18 years of age at the Screening Visit (Visit 1), of either gender and any race.
  2. Able and willing to provide written informed consent.
  3. Willing and able to comply with all study procedures.
  4. Patient-reported history of dry eye for at least 6 months prior to Visit 1.
  5. History of use or desire to use eye drops for dry eye symptoms within 6 months of Visit 1.
  6. Best corrected visual acuity (BCVA) of 0.7 logMAR or better (Snellen equivalent of 20/100 or better) in each eye at Visit 1.
  7. At least one eye, the same eye, must satisfy all criteria for Schirmer's Test, corneal fluorescein staining, conjunctival lissamine green staining, conjunctival redness, and CAE response.
  8. Female participants of childbearing potential must have a negative urine pregnancy test and must use adequate birth control throughout the study period. For non-sexually active females, abstinence may be regarded as an adequate method of birth control.

Exclusion Criteria:

  1. Clinically significant slit-lamp findings at Visit 1, including active blepharitis, meibomian gland dysfunction, severe lid margin inflammation, or active ocular allergies requiring therapeutic treatment, and/or findings that in the opinion of the investigator may interfere with study parameters. Participants with moderate to severe meibomian gland dysfunction, in the opinion of the investigator, are not eligible.
  2. Ongoing ocular infection, including bacterial, viral, or fungal infection, or active ocular inflammation at Visit 1.
  3. Contact lens wear within 7 days of Visit 1 or anticipated use of contact lenses during the study.
  4. LASIK surgery within the last 12 months.
  5. Female participant who is pregnant, nursing, or planning a pregnancy.
  6. Female participant of childbearing potential who is unwilling to submit a urine pregnancy test at Visit 1 and Visit 4, or at an early termination visit.
  7. Female participant of childbearing potential who is not using an acceptable method of birth control. Acceptable methods include hormonal contraceptives, mechanical contraception with spermicide and a barrier method, intrauterine device, or surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as adequate; however, if the participant becomes sexually active during the study, she must agree to use adequate birth control for the remainder of the study.
  8. Known allergy and/or sensitivity to the test article or its components.
  9. Any condition or situation that, in the investigator's opinion, may put the participant at significant risk, may confound study results, or may interfere significantly with participation in the study.
  10. Current enrollment in an investigational drug or device study or use of an investigational drug or device within 30 days of Visit 1.
  11. Unable or unwilling to follow instructions, including participation in all study assessments and visits.

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：随机化
  • 介入模型：并行分配
  • 屏蔽：四人间

武器和干预

参与者组/臂
干预/治疗
实验性的：RCI001 Ophthalmic Solution BID
Participants will receive 0.25% RCI001 Ophthalmic Solution, one drop in each eye twice daily (BID), for 4 weeks.
药品：RCI001 Ophthalmic Solution
RCI001 Ophthalmic Solution is a topical ophthalmic investigational drug containing 0.25% RCI001. Participants assigned to RCI001 treatment will receive one drop in each eye either twice daily (BID) or four times daily (QID), depending on the assigned treatment arm, for 4 weeks.
其他名称：
  • 0.25% RCI001 Ophthalmic Solution
安慰剂比较：Placebo Ophthalmic Solution BID
Participants will receive placebo ophthalmic solution, one drop in each eye twice daily (BID), for 4 weeks.
药品：Placebo Ophthalmic Solution
Placebo Ophthalmic Solution is a topical ophthalmic vehicle solution that has the same formulation as RCI001 Ophthalmic Solution but does not contain the active ingredient, RCI001. Participants assigned to placebo treatment will receive one drop in each eye either twice daily (BID) or four times daily (QID), depending on the assigned treatment arm, for 4 weeks.
其他名称：
  • Vehicle Ophthalmic Solution
实验性的：RCI001 Ophthalmic Solution QID
Participants will receive 0.25% RCI001 Ophthalmic Solution, one drop in each eye four times daily (QID), for 4 weeks.
药品：RCI001 Ophthalmic Solution
RCI001 Ophthalmic Solution is a topical ophthalmic investigational drug containing 0.25% RCI001. Participants assigned to RCI001 treatment will receive one drop in each eye either twice daily (BID) or four times daily (QID), depending on the assigned treatment arm, for 4 weeks.
其他名称：
  • 0.25% RCI001 Ophthalmic Solution
安慰剂比较：Placebo Ophthalmic Solution QID
Participants will receive placebo ophthalmic solution, one drop in each eye four times daily (QID), for 4 weeks.
药品：Placebo Ophthalmic Solution
Placebo Ophthalmic Solution is a topical ophthalmic vehicle solution that has the same formulation as RCI001 Ophthalmic Solution but does not contain the active ingredient, RCI001. Participants assigned to placebo treatment will receive one drop in each eye either twice daily (BID) or four times daily (QID), depending on the assigned treatment arm, for 4 weeks.
其他名称：
  • Vehicle Ophthalmic Solution

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Change From Baseline in Total Corneal Fluorescein Staining Score at Day 28
大体时间：Baseline to Day 28 (Week 4)
Change from baseline in total corneal fluorescein staining score in the study eye, assessed before Controlled Adverse Environment (CAE) exposure at Day 28 using the Ora Calibra Corneal and Conjunctival Staining Scale. Each ocular surface region is graded from 0 to 4, where 0 indicates no staining and 4 indicates confluent staining. The total score is the sum of the assessed regions, and higher scores indicate more staining and worse ocular surface disease.
Baseline to Day 28 (Week 4)
Change From Baseline in Ocular Discomfort Score at Day 28
大体时间：Baseline to Day 28 (Week 4)
Change from baseline in ocular discomfort score in the study eye, assessed before Controlled Adverse Environment (CAE) exposure at Day 28 using the Ora Calibra Ocular Discomfort Scale for Dry Eye. The scale ranges from 0 to 4, where 0 indicates no discomfort and 4 indicates constant discomfort. Higher scores indicate worse ocular discomfort.
Baseline to Day 28 (Week 4)

次要结果测量

结果测量
措施说明
大体时间
Change From Baseline in Fluorescein Staining Scores by Region
大体时间：Baseline to Day 14 and Day 28
Change from baseline in fluorescein staining scores by ocular region, including central, superior, inferior, temporal, and nasal regions, as well as summary staining scores, assessed using the Ora Calibra Corneal and Conjunctival Staining Scale. Each region is graded from 0 to 4, where 0 indicates no staining and 4 indicates confluent staining. Higher scores indicate more staining and worse ocular surface disease.
Baseline to Day 14 and Day 28
Change From Baseline in Conjunctival Lissamine Green Staining Scores by Region
大体时间：Baseline to Day 14 and Day 28
Change from baseline in conjunctival lissamine green staining scores by ocular region, including central, superior, inferior, temporal, and nasal regions, as well as summary staining scores, assessed using the Ora Calibra Corneal and Conjunctival Staining Scale. Each region is graded from 0 to 4, where 0 indicates no staining and 4 indicates confluent staining. Higher scores indicate more staining and worse ocular surface disease.
Baseline to Day 14 and Day 28
Change From Baseline in Conjunctival Redness Score
大体时间：Baseline to Day 14 and Day 28
Change from baseline in conjunctival redness score assessed using the Ora Calibra Conjunctival Redness Scale for Dry Eye. The scale ranges from 0 to 4, where 0 indicates normal without vasodilation and 4 indicates severe redness. Higher scores indicate worse conjunctival redness.
Baseline to Day 14 and Day 28
Change From Baseline in Schirmer's Test Score
大体时间：Baseline to Day 14 and Day 28
Change from baseline in Schirmer's test value. Schirmer's test measures tear production using the length of wetting on a Schirmer test strip after 5 minutes. The unit of measure is millimeters (mm), and higher values indicate greater tear production.
Baseline to Day 14 and Day 28
Change From Baseline in Tear Film Break-Up Time
大体时间：Baseline to Day 14 and Day 28
Change from baseline in tear film break-up time (TFBUT). TFBUT measures the time from eye opening to the first appearance of tear film break-up after fluorescein instillation. The unit of measure is seconds, and higher values indicate greater tear film stability.
Baseline to Day 14 and Day 28
Change From Baseline in Ocular Surface Disease Index Score
大体时间：Baseline to Day 14 and Day 28
Change from baseline in Ocular Surface Disease Index (OSDI) score assessed before Controlled Adverse Environment (CAE) exposure. The OSDI is a participant-reported questionnaire scored from 0 to 100, where higher scores indicate greater dry eye symptom severity and vision-related functional impairment.
Baseline to Day 14 and Day 28
Change From Baseline in Ocular Discomfort Scale Score
大体时间：Baseline to Day 14 and Day 28
Change from baseline in ocular discomfort score assessed using the Ora Calibra Ocular Discomfort Scale for Dry Eye. The scale ranges from 0 to 4, where 0 indicates no discomfort and 4 indicates constant discomfort. Higher scores indicate worse ocular discomfort.
Baseline to Day 14 and Day 28
Change From Baseline in Visual Analog Scale Symptom Scores
大体时间：Baseline to Day 14 and Day 28
Change from baseline in participant-reported dry eye symptom scores assessed using a visual analog scale (VAS). The VAS is scored from 0 to 100, where higher scores indicate greater symptom severity.
Baseline to Day 14 and Day 28
Change From Baseline in Ocular Discomfort and 4-Symptom Questionnaire Score
大体时间：Baseline to Day 14 and Day 28
Change from baseline in participant-reported ocular discomfort and dry eye symptom scores assessed using the Ora Calibra Ocular Discomfort and 4-Symptom Questionnaire for Dry Eye. Participants rate overall ocular discomfort, burning, dryness, grittiness, and stinging on a 0 to 5 scale, where 0 indicates none and 5 indicates worst. Higher scores indicate worse symptoms.
Baseline to Day 14 and Day 28
Change From Baseline in Daily Symptom Diary Scores
大体时间：Baseline to Day 28
Change from baseline in participant-reported daily dry eye symptom diary scores collected during the treatment period using the Ora Calibra Ocular Discomfort and 4-Symptom Questionnaire for Dry Eye. Symptoms are rated on a 0 to 5 scale, where 0 indicates none and 5 indicates worst. Higher scores indicate worse symptoms.
Baseline to Day 28

其他结果措施

结果测量
措施说明
大体时间
Incidence of Treatment-Emergent Adverse Events
大体时间：From first dose through Day 28
Number and percentage of participants with treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAEs leading to premature discontinuation. Adverse events will be coded using MedDRA and summarized by treatment group.
From first dose through Day 28
Change From Baseline in Visual Acuity
大体时间：Baseline to Day 28
Change from baseline in best-corrected visual acuity (BCVA). The unit of measure is change in visual acuity value, such as logMAR or ETDRS-based score, as collected in the study.
Baseline to Day 28
Change From Baseline in Intraocular Pressure
大体时间：Baseline to Day 28
Change from baseline in intraocular pressure (IOP) measured in each eye by contact tonometry. The unit of measure is mmHg.
Baseline to Day 28
Slit-Lamp Biomicroscopy Findings
大体时间：Baseline to Day 28
Number and percentage of participants with slit-lamp biomicroscopy findings, including clinically significant and non-clinically significant ocular findings, as determined by the investigator.
Baseline to Day 28
Dilated Fundoscopy Findings
大体时间：Baseline to Day 28
Number and percentage of participants with dilated fundoscopy findings, including clinically significant and non-clinically significant posterior segment findings, as determined by the investigator.
Baseline to Day 28
Mean Ora Calibra Drop Comfort Scale Score After Initial Dosing
大体时间：Immediately after initial dosing and at 1 and 2 minutes after initial dosing
Mean subject-reported drop comfort score assessed for each eye using the Ora Calibra Drop Comfort Scale after initial dosing at Visit 2. The Ora Calibra Drop Comfort Scale is an 11-point scale ranging from 0 to 10, where 0 indicates very comfortable and 10 indicates very uncomfortable.
Immediately after initial dosing and at 1 and 2 minutes after initial dosing
Subject-Reported Drop Comfort Descriptors After Initial Dosing
大体时间：3 minutes after initial dosing
Subject-reported drop comfort descriptors assessed using the Ora Calibra Drop Comfort Questionnaire at 3 minutes after initial dosing at Visit 2. Participants will select words that best describe how the eye drops feel in both eyes. The unit of measure will be the number and percentage of participants selecting each descriptor.
3 minutes after initial dosing

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Rudacure

调查人员

  • 研究主任：Yuseung Ha、Rudacure

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年9月1日

初级完成 (估计的)

2028年6月30日

研究完成 (估计的)

2028年8月30日

研究注册日期

首次提交

2026年5月12日

首先提交符合 QC 标准的

2026年6月1日

首次发布 (实际的)

2026年6月4日

研究记录更新

最后更新发布 (实际的)

2026年6月4日

上次提交的符合 QC 标准的更新

2026年6月1日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • RDC001_201

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

不

IPD 计划说明

Individual participant data will not be made available to other researchers. The study is sponsored by RudaCure Corporation and involves an investigational drug product. De-identified individual participant-level data are not planned for external sharing due to participant confidentiality, informed consent, regulatory, legal, and proprietary considerations. Aggregate study results may be disclosed through ClinicalTrials.gov, publications, and/or regulatory submissions, as applicable.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅